|
Q3 FY2026
As of May 31, 2026
|
Q2 FY2026
As of Feb 28, 2026
|
Q1 FY2026
As of Nov 30, 2025
|
Q4 FY2025
As of Aug 31, 2025
|
Q3 FY2025
As of May 31, 2025
|
Q2 FY2025
As of Feb 28, 2025
|
Q1 FY2025
As of Nov 30, 2024
|
Q4 FY2024
As of Aug 31, 2024
|
Q3 FY2024
As of May 31, 2024
|
Q2 FY2024
As of Feb 29, 2024
|
Q1 FY2024
As of Nov 30, 2023
|
Q4 FY2023
As of Aug 31, 2023
|
Q3 FY2023
As of May 31, 2023
|
Q2 FY2023
As of Feb 28, 2023
|
Q1 FY2023
As of Nov 30, 2022
|
Q4 FY2022
As of Aug 31, 2022
|
Q3 FY2022
As of May 31, 2022
|
Q2 FY2022
As of Feb 28, 2022
|
Q1 FY2022
As of Nov 30, 2021
|
Q4 FY2021
As of Aug 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | ||||||||||||||||||||
| Prepaid expenses and other receivables | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Available for sale Investment | ||||||||||||||||||||
| Equipment, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Convertible loan | ||||||||||||||||||||
| Short term Loan | ||||||||||||||||||||
| Due to a related party | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding | ||||||||||||||||||||
| Common stock, $0.0001 par value, 1,800,000,000 shares authorized, 1,475,768,095 and 553,962,206 shares issued and outstanding at May 31, 2026 and August 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Issuance of warrants | ||||||||||||||||||||
| Other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity (deficit) | ||||||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...
